Tag: NASDAQ:VNDA

The emergence of reports of a takeover bid has resulted in a considerable spike in the share price of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) during the current trading session. VNDA stock has risen impressively as of the latest check, increasing 24.16% to $6.27 on the US stock charts.

Vanda Takeover Proposal

Cycle Group sent a non-binding, unsolicited expression of interest, which Vanda Pharmaceuticals (VNDA) has confirmed receiving. On May 24, 2024, the Board of Directors was presented with a proposal to purchase all of the issued and existing VNDA shares for $8.00 in cash, which would value Vanda at $466 million in total.

All VNDA shareholders will get immediate and assured cash value from Cycle Group’s bid, which is 98% more than the closing share price on April 16, 2024—the day before Future Pak LLC’s original offer of $4.05 per share was made public.

It also offers a premium of 58% over Vanda’s closing share price on June 5, 2024, and a premium of 63% over Vanda’s closing share price on May 23, 2024, the day before Cycle Group’s application. This all-cash offer exceeds the cash portion of Future Pak’s revised proposal from May 7, 2024.

Financial Confidence And Strategic Review

Cycle Group, equipped with substantial cash reserves, has expressed strong confidence in securing committed financing for the transaction following limited due diligence. Cycle Group is optimistic about obtaining fully underwritten, binding commitment letters for any necessary debt financing prior to finalizing a definitive merger agreement, which will not include any financing contingency.

Cycle Group expects a quick and easy due diligence process because of its experience with Vanda and its broad industry understanding. It hopes to complete a definitive agreement in two to three weeks.

The Board of Directors will carefully evaluate and examine the expression of interest in order to determine what is best for the company and its investors in compliance with its fiduciary responsibility. It will also confer with independent financial and legal consultants.

After a revised takeover bid, Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is currently witnessing a surge in its share price on the market. As of the last check during the current session, VNDA shares have escalated by 16.63% to reach $5.64.

Vanda Pharmaceuticals (VNDA) has officially acknowledged receipt of an altered unsolicited proposition from Future Pak, LLC, aimed at acquiring the Company. The revised offer comprises a cash offer ranging from $7.25 to $7.75 per share, along with certain Contingent Value Rights (“CVRs”).

This updated proposition comes subsequent to Vanda’s evaluation and dismissal of a prior unsolicited bid from Future Pak, which proposed acquiring the Company within the same price range of $7.25 to $7.75 per share.

In adherence to its fiduciary obligations, and in collaboration with its autonomous financial and legal advisors, Vanda’s Board of Directors will meticulously scrutinize and assess the revised unsolicited proposition.

Earlier today, Future Pak announced to revise its offer for all outstanding common stock shares of Vanda, potentially increasing the value by approximately $4.37 per share compared to the preceding proposal unveiled on April 17, 2024.

This augmented offer, contingent on the full activation of the CVRs, represents a premium of 140% to 150% over Vanda’s closing share price of $4.84 on May 6, 2024, and a premium of 187% to 199% over the Company’s unaffected share price of $4.05 on April 16, 2024, the day preceding Future Pak’s initial public announcement regarding its intentions to acquire Vanda.

Future Pak escalated its consideration in a bid to facilitate progress for Vanda, proposing a potential framework for CVRs that could substantially elevate the total consideration. The company has endeavored to adopt a constructive approach by offering additional value contingent upon favorable performance in the commercial sector, alongside substantial value stemming from the monetization of the pipeline.

The revised offer now includes value associated with Fanapt and Tradipitant, with these supplementary components furnishing substantial benefits for Vanda shareholders through enhanced participation and establishing a solid foundation for constructive dialogue with Future Pak.

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has seen a remarkable surge in its stock price, catapulting by 34.86% to $5.46 per share at last check during the current session. This surge follows the rejection of a takeover bid, propelling VNDA shares on an upward trajectory.

In a statement released by Vanda Pharmaceuticals (VNDA), it has been disclosed that Future Pak, LLC has been keen on acquiring all Vanda shares since March 2024, having submitted numerous unsolicited proposals. The latest offer, dated April 1, presented a price range of $7.25 to $7.75 per share.

Following a meticulous review conducted in adherence to its fiduciary duties, Vanda’s Board of Directors, alongside its independent financial and legal advisors, has unanimously concluded that these Conditional Proposals are not aligned with the best interests of Vanda Pharmaceuticals and its shareholders.

The Board perceives these Conditional Proposals as opportunistic attempts to procure the company’s shares at a markdown to Vanda Pharmaceuticals’ intrinsic value, potentially leading to a significant value transfer to Future Pak, to the detriment of VNDA shareholders.

This includes an estimated $6.751 per share in cash and marketable securities. The latest proposal from Future Pak offers a premium of only 7% to 15% over this cash balance, assigning minimal value to Vanda Pharmaceuticals’ substantial revenue stream and pipeline.

Subsequently, in a separate announcement, Vanda Pharmaceuticals has implemented a temporary stockholder rights plan to safeguard the interests of shareholders and optimize value for all stockholders. The Rights Plan has taken effect immediately. The Rights Plan is designed to empower shareholders to realize the full value of their investment in Vanda Pharmaceuticals.

The Rights Plan will also decrease the likelihood of any entity, individual, or group gaining control of the company through open-market accumulation without offering all shareholders an appropriate control premium or affording the Board adequate opportunity to make informed decisions and take actions that align with the best interests of all shareholders.